These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22963050)

  • 1. Stabilization of multiple metastatic epithelioid sarcoma under treatment with sunitinib malate.
    Penot P; Bouaziz JD; Battistella M; Kerob D; Pagès C; Vilmer C; Basset-Seguin N; Madjessli N; Comte C; Farges C; Bagot M; le Maignan C; Lebbé C
    Br J Dermatol; 2013 Apr; 168(4):871-3. PubMed ID: 22963050
    [No Abstract]   [Full Text] [Related]  

  • 2. Refractory cutaneous angiosarcoma successfully treated with sunitinib.
    Lu HJ; Chen PC; Yen CC; Hsiao FC; Tzeng CH; Ma H; Shiau CY; Chao TC
    Br J Dermatol; 2013 Jul; 169(1):204-6. PubMed ID: 23383874
    [No Abstract]   [Full Text] [Related]  

  • 3. A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.
    Lewin J; Khamly KK; Young RJ; Mitchell C; Hicks RJ; Toner GC; Ngan SY; Chander S; Powell GJ; Herschtal A; Te Marvelde L; Desai J; Choong PF; Stacker SA; Achen MG; Ferris N; Fox S; Slavin J; Thomas DM
    Br J Cancer; 2014 Dec; 111(12):2254-61. PubMed ID: 25321190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma.
    Guida FM; Santoni M; Conti A; Burattini L; Savini A; Zeppola T; Caricato M; Cascinu S; Tonini G; Santini D
    Crit Rev Oncol Hematol; 2014 Dec; 92(3):208-17. PubMed ID: 25151214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.
    Campos SM; Penson RT; Matulonis U; Horowitz NS; Whalen C; Pereira L; Tyburski K; Roche M; Szymonifka J; Berlin S
    Gynecol Oncol; 2013 Feb; 128(2):215-20. PubMed ID: 22885865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic hepatic epithelioid hemangio-endothelioma: long-term response to sunitinib malate.
    Saada E; Saint Paul MC; Gugenheim J; Follana P; François E
    Oncol Res Treat; 2014; 37(3):124-6. PubMed ID: 24685916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer.
    Harshman L; Srinivas S
    Onkologie; 2008 Sep; 31(8-9):432-3. PubMed ID: 18787349
    [No Abstract]   [Full Text] [Related]  

  • 8. An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
    Cardoso F; Canon JL; Amadori D; Aldrighetti D; Machiels JP; Bouko Y; Verkh L; Usari T; Kern KA; Giorgetti C; Dirix L
    Breast; 2012 Dec; 21(6):716-23. PubMed ID: 23022045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelioid sarcoma of the hand.
    Tsur H; Lipsker E
    Ann Plast Surg; 1982 May; 8(5):420-2. PubMed ID: 7114752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma.
    Kahl C; Hilgendorf I; Freund M; Casper J
    Onkologie; 2008 Sep; 31(8-9):485. PubMed ID: 18787358
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
    Haas NB; Manola J; Uzzo RG; Flaherty KT; Wood CG; Kane C; Jewett M; Dutcher JP; Atkins MB; Pins M; Wilding G; Cella D; Wagner L; Matin S; Kuzel TM; Sexton WJ; Wong YN; Choueiri TK; Pili R; Puzanov I; Kohli M; Stadler W; Carducci M; Coomes R; DiPaola RS
    Lancet; 2016 May; 387(10032):2008-16. PubMed ID: 26969090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months.
    Straka C; Kim DW; Timmerman RD; Pedrosa I; Jacobs C; Brugarolas J
    J Clin Oncol; 2013 Aug; 31(23):e401-3. PubMed ID: 23796996
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
    Atkinson BJ; Kalra S; Wang X; Bathala T; Corn P; Tannir NM; Jonasch E
    J Urol; 2014 Mar; 191(3):611-8. PubMed ID: 24018239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell carcinoma: at least 12-month follow-up.
    Zhang CJ; Zhao PJ; Li XS; Zhao J; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; He ZS; Jin J; Zhou LQ
    Chin Med J (Engl); 2013; 126(15):2826-9. PubMed ID: 23924450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and tolerability of a sunitinib 3-week administration schedule in metastatic renal cell carcinoma patients: report of three cases.
    Neri B; Vannini A; Tassi R; Brugia M; Rangan S; Rediti M; Cerullo C
    Oncol Res; 2012; 20(5-6):259-64. PubMed ID: 23581233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series.
    Italiano A; Kind M; Cioffi A; Maki RG; Bui B
    Target Oncol; 2013 Sep; 8(3):211-213. PubMed ID: 23292310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
    Shi HZ; Tian J; Chen X; Wang D; Li CL
    Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience.
    Ezz El Din M
    Clin Genitourin Cancer; 2017 Jun; 15(3):e455-e462. PubMed ID: 28392154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.
    Lee JL; Kim MK; Park I; Ahn JH; Lee DH; Ryoo HM; Song C; Hong B; Hong JH; Ahn H
    Ann Oncol; 2015 Nov; 26(11):2300-5. PubMed ID: 26347107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy.
    Lee SH; Bang YJ; Mainwaring P; Ng C; Chang JW; Kwong P; Li RK; Sriuranpong V; Toh CK; Yuan J; Pitman Lowenthal S; Chung HC
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):237-45. PubMed ID: 24576311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.